Literature DB >> 26405110

Apheresis to Treat Preeclampsia: Insights, Opportunities and Challenges.

Thomas R Easterling1.   

Abstract

Keywords:  VEGF; preeclampsia; sFlt-1

Mesh：

Substances：

Year:  2015        PMID： 26405110      PMCID： PMC4769212          DOI： 10.1681/ASN.2015070794

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  10 in total

1.  Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta.

Authors:  Kerry McMahon; S Ananth Karumanchi; Isaac E Stillman; Peter Cummings; Dorothy Patton; Thomas Easterling
Journal:  Am J Obstet Gynecol       Date:  2013-08-29       Impact factor: 8.661

2.  Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia.

Authors:  Maged M Costantine; Esther Tamayo; Fangxian Lu; Egle Bytautiene; Monica Longo; Gary D V Hankins; George R Saade
Journal:  Obstet Gynecol       Date:  2010-07       Impact factor: 7.661

3.  Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia.

Authors:  Karin A Fox; Monica Longo; Esther Tamayo; Talar Kechichian; Egle Bytautiene; Gary D V Hankins; George R Saade; Maged M Costantine
Journal:  Am J Obstet Gynecol       Date:  2011-06-29       Impact factor: 8.661

4.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.

Authors:  Ravi Thadhani; Henning Hagmann; Wiebke Schaarschmidt; Bernhard Roth; Tuelay Cingoez; S Ananth Karumanchi; Julia Wenger; Kathryn J Lucchesi; Hector Tamez; Tom Lindner; Alexander Fridman; Ulrich Thome; Angela Kribs; Marco Danner; Stefanie Hamacher; Peter Mallmann; Holger Stepan; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2015-09-24       Impact factor: 10.121

5.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Pravastatin for the prevention of preeclampsia in high-risk pregnant women.

Authors:  Maged M Costantine; Kirsten Cleary
Journal:  Obstet Gynecol       Date:  2013-02       Impact factor: 7.661

7.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

8.  Hemodynamically-directed atenolol therapy is associated with a blunted rise in maternal sFLT-1 levels during pregnancy.

Authors:  Darcy B Carr; Lan T Tran; Debra A Brateng; Cydney Kawamura; Jane B Shofer; S Ananth Karumanchi; Thomas R Easterling
Journal:  Hypertens Pregnancy       Date:  2009-02       Impact factor: 2.108

Review 9.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Authors:  E Abalos; L Duley; D W Steyn; D J Henderson-Smart
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 10.  Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia.

Authors:  Wenda Ramma; Asif Ahmed
Journal:  J Reprod Immunol       Date:  2014-01-16       Impact factor: 4.054
  10 in total
  2 in total

Review 1.  A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy.

Authors:  Sayuri Padayachee; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2019-07-24       Impact factor: 5.369

Review 2.  Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches.

Authors:  Zaher Armaly; Jimmy E Jadaon; Adel Jabbour; Zaid A Abassi
Journal:  Front Physiol       Date:  2018-07-25       Impact factor: 4.566
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.